Summary: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Top Publications

  1. Lennox J, Landovitz R, Ribaudo H, Ofotokun I, Na L, Godfrey C, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461-71 pubmed publisher
    ..Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate,..
  2. Capetti A, Piconi S, Landonio S, Rizzardini G, Perno C. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?. J Acquir Immune Defic Syndr. 2009;50:233-4 pubmed publisher
  3. Florence E, de Wit S, Castagna A, Ribera E, Hill A, Vanaken H, et al. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. Int J STD AIDS. 2010;21:224-5 pubmed publisher
  4. Xiang N, James M, Walters S, Bamford A, Foster C. Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study. HIV Med. 2014;15:635-6 pubmed publisher
  5. Tashima K, Mollan K, Na L, Gandhi R, Klingman K, Fichtenbaum C, et al. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials. 2015;16:147-56 pubmed publisher
    ..options for treatment-experienced participants consisting of 3-4 of the following agents: raltegravir (RAL), darunavir (DRV)/ritonavir, tipranavir (TPV)/ritonavir, etravirine (ETR), maraviroc (MVC), and enfuvirtide (ENF)...
  6. Antoniou T, Szadkowski L, Walmsley S, Cooper C, Burchell A, Bayoumi A, et al. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. BMC Infect Dis. 2017;17:266 pubmed publisher
    Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking...
  7. Eyer Silva W, Silva G, Ferry F, Pinto J. Facial botryomycosis-like pyoderma in an HIV-infected patient: remission after initiation of darunavir and raltegravir. Rev Soc Bras Med Trop. 2017;50:277-279 pubmed publisher
    ..Complete clinical remission was only achieved 5 years later when a novel antiretroviral regimen composed of darunavir and raltegravir was initiated.